Managing cancer-related anorexia/cachexia.
Cancer-related anorexia/cachexia (CAC) is a complex phenomenon in which metabolic abnormalities, proinflammatory cytokines produced by the host immune system, circulating tumour-derived catabolic factors, decreased food intake, and probably additional unknown factors, all play different roles. This review examines the mechanisms of CAC and its management. All the potential modalities of intervention from nutritional to pharmacological approaches are included with a clear distinction between unproven, investigational and well established treatments. Among the latter, the progestogens are currently considered the most effective and safest drugs for the management of CAC. Agents currently under investigation for CAC include thalidomide, pentoxifylline and melatonin, which most probably act on cytokine release, and clenbuterol, which acts on muscle mass and to antagonise protein wasting. Our personal experience with the synthetic progestogens megestrol and medroxyprogesterone supports their use as first-line agents. In addition, our work on the potential role of antioxidant agents in counteracting the oxidative stress, which appears to be involved in CAC, shows them to be promising agents when used in combination chemotherapy regimens either alone or with other 'biologics'. There is an ongoing need for quality of life questionnaires which specifically address the most significant symptoms present in patients with CAC.
Mantovani
G
G
Department of Medical Oncology, University of Cagliari, Italy. mantovan@pacs.unica.it
Macciò
A
A
Massa
E
E
Madeddu
C
C
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000855:Anorexia / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001066:Appetite; D002100:Cachexia / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D008535:Megestrol / Q000627:therapeutic use; D009369:Neoplasms / Q000150:complications*; D011372:Progestins / Q000627:therapeutic use; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic
D000305:Adrenal Cortex Hormones; D018931:Antineoplastic Agents, Hormonal; D011372:Progestins; D008535:Megestrol